Pharmacological action

Synthetic analogue of GnRH. After an initial short-term increase of gonadotropin causes desensitization of the gonadotrophic function of the pituitary and suppress the secretion of LH and FSH.


Diseases in which you want to lower the level of sex hormones (including the symptomatic treatment of hormone carcinoma of the prostate gland). Endometriosis, uterine fibroid, in vitro fertilization.

To reduce the size of uterine fibroids in the upcoming cases surgical removal of fibroids and hysterectomies, endometriosis, confirmed laparoscopically, when indicated for the suppression of ovarian function and no need for surgical intervention.

Dosage regimen

Solo, depending on the evidence used dosage form and regimen.

Side effect

On the part of the reproductive system: vaginal dryness, pain during intercourse, weight gain, decreased libido (women and men), the appearance of spotting from the vagina, gynecomastia (in men), impotence.

From the CNS and peripheral nervous system: rarely - headache, sleep disorders, depression, fatigue, paresthesia, visual disturbances, back pain, irritability.

On the part of the digestive system: nausea, increased cholesterol in plasma, increased hepatic enzymes.

Other: flushing with profuse sweating, decrease in bone density; rare - allergic reactions.


Polycystic ovary syndrome, pregnancy, lactation, hypersensitivity to triptorelinu.


Side-effect is reversible. Prior therapy should be completely excluded pregnancy. Menstruation usually occurs 3 months after the last injection of depot-forms, but in some cases later.

In the course of therapy should regularly monitor the level of sex steroid hormones in plasma (men and women), as well as the size of myoma (including using ultrasound). It should be borne in mind that a disproportionately rapid decline in the uterus, compared with the size of fibroids, in some cases can cause bleeding and sepsis.

To prevent hyperstimulation should carefully monitor the growth of follicles and luteal phase, especially in polycystic ovaries. During the first month of therapy, women should use non-hormonal contraceptives.

In men, early treatment may increase the level of testosterone in the plasma, so the 1 st week of therapy is recommended careful monitoring of patients and, when necessary, symptomatic therapy.